ArticleCureus2025
The Effect of Neoadjuvant Treatment on the Number of Lymph Node Dissection and Prognosis in Locally Advanced Rectal Cancer and Other Factors Affecting Lymph Node Metastasis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The current standard treatment for locally advanced rectal cancer is neoadjuvant chemoradiotherapy (CRT), followed by total mesorectal excision. The removal of at least 12 lymph nodes is recommended to accurately stage the disease and predict prognosis, but surgery following neoadjuvant therapy often fails to reach all 12 lymph nodes. This study investigated the changes in lymph node count following chemoradiotherapy and the factors contributing to this change. We also examined the impact of these factors on prognosis. Materials and methods A retrospective review was conducted on 250 patients diagnosed with locally advanced rectal cancer between 2012 and 2019. These patients were divided into two groups: those who received neoadjuvant chemoradiotherapy (NACRT) and those who did not. The number of lymph nodes between the two groups and the factors affecting this number were investigated. The distribution of variables was measured using the Kolmogorov-Smirnov test. Cox regression (univariate-multivariate) and Kaplan-Meier regression were used for survival analysis. Results Of the patients, 135 received neoadjuvant chemoradiotherapy, and 115 began treatment with initial surgery. The number of lymph nodes was statistically significantly lower in the chemoradiotherapy group (9.5 versus 15.1, p=0.000). Patient comorbidities influenced the initial treatment option and directly affected the number of lymph nodes. Furthermore, tumor location, the use of total mesorectal excision, and the pathological response of the tumor to chemoradiotherapy significantly affected the number of lymph nodes. Multivariate analysis revealed that circumferential resection margin (CRM) negativity was associated with disease-free survival (DFS), while overall survival (OS) was associated with metastatic lymph node status (p=0.01), the lack of neoadjuvant therapy (p=0.00), and impaired total mesorectal excision integrity (p=0.01). Conclusion Chemoradiotherapy is the first-line treatment for locally advanced rectal cancer. Chemoradiotherapy reduces the number of lymph nodes. We advocate that pathological tumor response, in addition to lymph node count, should be considered to predict patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.